Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million Series C financing.
{iframe}https://graybug.com/graybug-vision-secures-80-million-of-additional-funding-to-advance-its-potentially-transformative-retina-and-glaucoma-clinical-programs/{/iframe}